Squamous Cell Carcinoma

New data on combination treatments for melanoma

Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according ...

Sep 29, 2014
popularity not rated yet | comments 0

Gene linked to development of skin cancer in mice

(Medical Xpress)—New research on an enzyme linked to cancer development shows that 37 percent of mice that produce excessive quantities of the enzyme developed skin tumors within four to 12 months of birth, ...

Sep 23, 2014
popularity not rated yet | comments 0

Squamous cell carcinoma (SCC or SqCC) is a form of skin cancer. Skin cancers fall into two groups, melanoma and non-melanoma; squamous cell carcinoma is a non-melanoma cancer. It is one of the most common cancers in humans and other animals.

Squamous cells are a type of epithelium cell forming the outermost layers of the skin and some organs in the body. Squamous cell carcinoma usually occurs on the skin, especially portions commonly exposed to the Sun, the face, ears, neck, hands, or arm. The main symptom is a growing bump that may have a rough, scaly surface and flat reddish patches. It may also occur inside the body wherever squamous cells are found, including the esophagus, urinary bladder, prostate, lung, vagina, and cervix, among others.

Despite the common name, squamous cell carcinomas arising in different body sites can show tremendous differences in their presenting signs and symptoms, natural history, prognosis, and response to treatment.

Though the use of these terms has been decreasing in the literature, SqCC is still sometimes referred to as "epidermoid carcinoma" and "squamous cell epithelium". During its earliest stages, it is sometimes known as "Bowen's disease".

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Ebola vaccine promising in first human trials

Researchers say they are one step closer to developing an Ebola vaccine, with a Phase 1 trial showing promising results, but it will be months at the earliest before it can be used in the field.

Team finds an off switch for pain

In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health (NIH) and other academic institutions have d ...